Intranasal corticosteroids drugs

Midazolam, when taken during the third trimester of pregnancy, may cause risk to the neonate, including benzodiazepine withdrawal syndrome, with possible symptoms including hypotonia , apnoeic spells, cyanosis , and impaired metabolic responses to cold stress. Symptoms of hypotonia and the neonatal benzodiazepine withdrawal syndrome have been reported to persist from hours to months after birth. [46] Other neonatal withdrawal symptoms include hyperexcitability, tremor, and gastrointestinal upset (diarrhea or vomiting). Breastfeeding by mothers using midazolam is not recommended. [47]

Intranasal corticosteroids drugs

intranasal corticosteroids drugs

Media:

intranasal corticosteroids drugsintranasal corticosteroids drugsintranasal corticosteroids drugsintranasal corticosteroids drugsintranasal corticosteroids drugs